デフォルト表紙
市場調査レポート
商品コード
947807

世界のIBD (炎症性腸疾患) 市場:2019-2025年

Global Inflammatory Bowel Disease (IBD) Therapeutics Market 2019-2025

出版日: | 発行: Orion Market Research Pvt Ltd | ページ情報: 英文 | 納期: 2~3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=115.11円
世界のIBD (炎症性腸疾患) 市場:2019-2025年
出版日: 2020年03月28日
発行: Orion Market Research Pvt Ltd
ページ情報: 英文
納期: 2~3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のIBD (炎症性腸疾患) の市場は予測期間中、約5.0%のCAGRで成長すると予測されています。クローン病や潰瘍性大腸炎などのIBDの罹患率の拡大が同市場の成長を推進しています。また、新製品の発売、M&A、政府との協力、スタートアップへの投資、技術開発など、参入事業者によるさまざまな成長戦略の導入も同市場の成長に大きく貢献しています。

当レポートでは、世界のIBD (炎症性腸疾患) の市場を調査し、市場の定義と概要、市場成長への各種影響因子の分析、関連法規制、市場規模の推移・予測、疾患区分・治療法など各種区分別の内訳、地域・主要国別の詳細分析、競合環境、企業シェア、主要企業のプロファイルなどをまとめています。

第1章 レポート概要

第2章 市場概要・考察

  • 調査範囲
  • アナリストの見解・現在の市場動向
  • 法規制

第3章 競合情勢

  • 企業シェア分析
  • 主要戦略の分析
  • 主要企業の分析
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の展開

第4章 市場影響因子

  • 成長推進因子
  • 成長抑制因子
  • 市場機会

第5章 市場分析・予測:各種区分別

  • 疾患別
    • 潰瘍性大腸炎
    • クローン病
  • 治療別
    • 手術
    • 抗炎症薬

第6章 地域分析

  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • その他
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • その他
  • その他の地域

第7章 企業プロファイル

  • Abbott Laboratories
  • AbbVie Inc.
  • Allergan, PLC
  • Boehringer Ingelheim International GmbH
  • Celgene Corp.
  • Daiichi Sankyo Co. Ltd.
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services Inc.
  • Laboratory Corporation of America Holdings
  • Mercator Pharmaceutical Solutions
  • Pfizer Inc.
  • Pharmacosmos A/S
  • RPG Life Sciences Ltd.
  • Sanofi S.A.
  • Takeda pharmaceutical Co., Ltd.
  • UCB, Inc.
  • Vifor Pharma Group
図表

List of Tables

  • 1. GLOBAL IBD THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2018-2025 ($ MILLION)
  • 2. GLOBAL ULCERATIVE COLITIS MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 3. GLOBAL CROHN'S DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 4. GLOBAL IBD THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2018-2025 ($ MILLION)
  • 5. GLOBAL SURGERY MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 6. GLOBAL ANTI- INFLAMMATORY DRUG ADMINISTRATION MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 7. GLOBAL IBD THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2018-2025 ($ MILLION)
  • 8. NORTH AMERICAN IBD THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
  • 9. NORTH AMERICAN IBD THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2018-2025 ($ MILLION)
  • 10. NORTH AMERICAN IBD THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2018-2025 ($ MILLION)
  • 11. EUROPEAN IBD THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
  • 12. EUROPEAN IBD THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2018-2025 ($ MILLION)
  • 13. EUROPEAN IBD THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2018-2025 ($ MILLION)
  • 14. ASIA-PACIFIC IBD THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
  • 15. ASIA-PACIFIC IBD THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2018-2025 ($ MILLION)
  • 16. ASIA-PACIFIC IBD THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2018-2025 ($ MILLION)
  • 17. REST OF THE WORLD IBD THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2018-2025 ($ MILLION)
  • 18. REST OF THE WORLD IBD THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2018-2025 ($ MILLION)

List of Figures

  • 1. GLOBAL IBD THERAPEUTICS MARKET SHARE BY DISEASE TYPE, 2018 VS 2025 (%)
  • 2. GLOBAL IBD THERAPEUTICS MARKET SHARE BY TREATMENT TYPE, 2018 VS 2025 (%)
  • 3. US IBD THERAPEUTICS MARKET SIZE, 2018-2025 ($ MILLION)
  • 4. CANADA IBD THERAPEUTICS MARKET SIZE, 2018-2025 ($ MILLION)
  • 5. UK IBD THERAPEUTICS MARKET SIZE, 2018-2025 ($ MILLION)
  • 6. FRANCE IBD THERAPEUTICS MARKET SIZE, 2018-2025 ($ MILLION)
  • 7. GERMANY IBD THERAPEUTICS MARKET SIZE, 2018-2025 ($ MILLION)
  • 8. ITALY IBD THERAPEUTICS MARKET SIZE, 2018-2025 ($ MILLION)
  • 9. SPAIN IBD THERAPEUTICS MARKET SIZE, 2018-2025 ($ MILLION)
  • 10. ROE IBD THERAPEUTICS MARKET SIZE, 2018-2025 ($ MILLION)
  • 11. INDIA IBD THERAPEUTICS MARKET SIZE, 2018-2025 ($ MILLION)
  • 12. CHINA IBD THERAPEUTICS MARKET SIZE, 2018-2025 ($ MILLION)
  • 13. JAPAN IBD THERAPEUTICS MARKET SIZE, 2018-2025 ($ MILLION)
目次
Product Code: OMR2021235

Global Inflammatory Bowel Disease (IBD) Therapeutics Market Size, Share & Trends Analysis Report by Disease Type (Ulcerative Colitis and Crohn's Disease), By Treatment Type (Surgery and Anti- Inflammatory Drug Administration) and Forecast 2019-2025

The global IBD therapeutics market is estimated to grow significantly at a CAGR of around 5.0% during the forecast period. The rise in the number of IBD such as Crohn's disease and ulcerative colitis is augmenting the growth of the global IBD therapeutics market. The increasing prevalence of IBD results in the need for research for the treatment of IBD and innovations in healthcare systems to manage this complex and costly disease. According to the CDC in the US, the incidence rate for Crohn's disease was 3.1 to 14.6 cases per 100,000 people per year in 2015. The incidence rate of ulcerative colitis was 2.2 to 14.3 cases per 100,000 people per year in 2015. Moreover, the prevalence of IBD in Europe is increasing, according to the European Federation of Crohn's & Ulcerative Colitis Associations (EFCCA), there were 3.4 million cases of IBD in 2016. According to the WHO, the highest rates of IBD are found in, developed countries including the US and UK.

The global IBD therapeutics market is segmented on the basis of disease type and treatment type. The disease type segment includes ulcerative colitis and Crohn's disease. Crohn's disease segment is estimated to dominate the market. The growth of the segment is attributed to the comparatively higher incidence of Crohn's disease than ulcerative colitis. For Crohn's and ulcerative colitis, the development of minimally invasive methods has been evolved with more caution as compared to other colorectal diseases. This is primarily due to disease-related characteristics that are concerned with IBD. The treatment type segment is further segmented into anti-inflammatory drugs and surgery. There is a range of anti-inflammatory drugs used for the treatment of IBD, such as immunosuppressants (methotrexate, ciclosporin, and azathioprine), steroids and biological drugs. These are usually the first step in the treatment of IBD.

The companies which are contributing to the growth of the global IBD therapeutics market include Abbott Laboratories, AbbVie Inc., Allergan, PLC Celgene Corp., Eli Lilly and Co., Johnson & Johnson Services Inc., Pfizer Inc., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, and technological advancements to stay competitive in the market.

Research Methodology

The market study of global IBD therapeutics market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include:

  • Financial reports of companies involved in the market.
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.

Market Segmentation

1. Global IBD Market Research and Analysis by Disease Type

2. Global IBD Market Research and Analysis by Treatment type

The Report Covers:

  • Comprehensive research methodology of the global IBD therapeutics market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global IBD therapeutics market.
  • Insights about market determinants which are stimulating the global IBD therapeutics market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion
  • 2.3. Rules & Regulations

3. Competitive Landscape

  • 3.1. Company Share Analysis
  • 3.2. Key Strategy Analysis
  • 3.3. Key Company Analysis
    • 3.3.1. AbbVie Inc.
      • 3.3.1.1. Overview
      • 3.3.1.2. Financial Analysis
      • 3.3.1.3. SWOT Analysis
      • 3.3.1.4. Recent Developments
    • 3.3.2. Allergan, PLC
      • 3.3.2.1. Overview
      • 3.3.2.2. Financial Analysis
      • 3.3.2.3. SWOT Analysis
      • 3.3.2.4. Recent Developments
    • 3.3.3. Johnson & Johnson Services Inc.
      • 3.3.3.1. Overview
      • 3.3.3.2. Financial Analysis
      • 3.3.3.3. SWOT Analysis
      • 3.3.3.4. Recent Developments
    • 3.3.4. Pfizer Inc.
      • 3.3.4.1. Overview
      • 3.3.4.2. Financial Analysis
      • 3.3.4.3. SWOT Analysis
      • 3.3.4.4. Recent Developments
    • 3.3.5. Eli Lilly and Co.
      • 3.3.5.1. Overview
      • 3.3.5.2. Financial Analysis
      • 3.3.5.3. SWOT Analysis
      • 3.3.5.4. Recent Developments

4. Market Determinants

  • 4.1. Motivators
  • 4.2. Restraints
  • 4.3. Opportunities

5. Market Segmentation

  • 5.1. Global IBD Therapeutics Market by Disease Type
    • 5.1.1. Ulcerative Colitis
    • 5.1.2. Crohn's Disease
  • 5.2. Global IBD Therapeutics Market by Treatment Type
    • 5.2.1. Surgery
    • 5.2.2. Anti- Inflammatory Drug Administration
      • 5.2.2.1. Steroids
      • 5.2.2.2. Immunosuppressant
      • 5.2.2.3. Biological Drugs
      • 5.2.2.4. Amino salicylates
      • 5.2.2.5. Others

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. France
    • 6.2.4. Italy
    • 6.2.5. Spain
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. Abbott Laboratories
  • 7.2. AbbVie Inc.
  • 7.3. Allergan, PLC
  • 7.4. Boehringer Ingelheim International GmbH
  • 7.5. Celgene Corp.
  • 7.6. Daiichi Sankyo Co. Ltd.
  • 7.7. Eli Lilly and Co.
  • 7.8. F. Hoffmann-La Roche AG
  • 7.9. GlaxoSmithKline PLC
  • 7.10. Johnson & Johnson Services Inc.
  • 7.11. Laboratory Corporation of America Holdings
  • 7.12. Mercator Pharmaceutical Solutions
  • 7.13. Pfizer Inc.
  • 7.14. Pharmacosmos A/S
  • 7.15. RPG Life Sciences Ltd.
  • 7.16. Sanofi S.A.
  • 7.17. Takeda pharmaceutical Co., Ltd.
  • 7.18. UCB, Inc.
  • 7.19. Vifor Pharma Group